Keros reports second-quarter 2026 results as Phase 2 rinvatercept DMD trial gets underway

Keros Therapeutics reported second-quarter 2026 results on August 3, 2026, highlighting the start of a new clinical study for its lead drug candidate. CEO Jasbir S. Seehra said the company had initiated its Phase 2 clinical trial evaluating rinvatercept in patients with Duchenne muscular dystrophy, calling it an important milestone for the program.¹

Seehra pointed to earlier data supporting the move into Phase 2, noting that in the Phase 1 trial in healthy volunteers, rinvatercept showed pharmacological activity reflected in increases in muscle mass and bone mineral density, along with a decrease in fat mass.¹ The company said it continues to expect initial data from the Phase 2 trial in the first half of 2027.¹

Beyond rinvatercept, the company described its DMD program alongside earlier-stage work, noting that rinvatercept, its lead product candidate, is being developed for DMD as well as amyotrophic lateral sclerosis.¹ Its other program, elritercept, is aimed at treating cytopenias such as anemia and low platelet counts in patients with myelodysplastic syndrome and in those with myelofibrosis.¹

On finances, Keros reported a net loss of $28.7 million for the quarter, compared with a $30.7 million loss a year earlier.¹ The company attributed the narrower loss largely to Takeda-related license revenue booked in 2025 and lower research and development spending in the current quarter.¹

Cash and equivalents stood at $257.6 million as of June 30, 2026, down from $287.4 million at the end of 2025.¹ Keros said, based on its current planning assumptions, that its cash position should be sufficient to cover operating expenses and capital spending needs into the first half of 2028.¹